Boston Scientific (NYSE:BSX) Downgraded by Wall Street Zen to Hold

Wall Street Zen downgraded shares of Boston Scientific (NYSE:BSX) from a buy rating to a hold rating in a research note released on Sunday morning.

BSX has been the topic of a number of other reports. BTIG Research dropped their price target on Boston Scientific from $65.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday, July 29th. Evercore set a $65.00 price objective on Boston Scientific in a research note on Monday, July 6th. Mizuho dropped their target price on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 15th. Piper Sandler reiterated an “overweight” rating and issued a $65.00 target price on shares of Boston Scientific in a research note on Friday, June 12th. Finally, Weiss Ratings downgraded shares of Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, July 7th. Twenty-four analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $71.62.

Boston Scientific Trading Up 0.0%

Boston Scientific stock opened at $46.75 on Friday. Boston Scientific has a 1 year low of $42.20 and a 1 year high of $109.50. The firm’s 50-day moving average is $46.13 and its 200-day moving average is $62.02. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The company has a market cap of $69.48 billion, a P/E ratio of 18.93, a PEG ratio of 1.02 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.36%. The firm had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same quarter in the prior year, the business earned $0.75 earnings per share. Boston Scientific’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities analysts expect that Boston Scientific will post 3.3 earnings per share for the current year.

Boston Scientific announced that its Board of Directors has authorized a share repurchase program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its stock is undervalued.

Insider Buying and Selling

In other news, Director Edward J. Ludwig bought 3,580 shares of the business’s stock in a transaction on Wednesday, May 20th. The stock was purchased at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the transaction, the director directly owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. This trade represents a 16.44% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David C. Habiger bought 2,250 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average cost of $55.92 per share, with a total value of $125,820.00. Following the purchase, the director directly owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. This represents a 19.35% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought a total of 9,800 shares of company stock valued at $554,012 over the last quarter. Corporate insiders own 0.34% of the company’s stock.

Hedge Funds Weigh In On Boston Scientific

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Cary Street Partners Financial LLC boosted its stake in Boston Scientific by 16.7% in the 2nd quarter. Cary Street Partners Financial LLC now owns 25,092 shares of the medical equipment provider’s stock worth $1,071,000 after purchasing an additional 3,597 shares during the period. Farther Finance Advisors LLC boosted its position in shares of Boston Scientific by 28.9% in the second quarter. Farther Finance Advisors LLC now owns 28,699 shares of the medical equipment provider’s stock worth $1,227,000 after buying an additional 6,427 shares during the period. Sequoia Financial Advisors LLC grew its holdings in shares of Boston Scientific by 2.3% during the second quarter. Sequoia Financial Advisors LLC now owns 49,355 shares of the medical equipment provider’s stock valued at $2,106,000 after buying an additional 1,119 shares in the last quarter. Simplify Asset Management Inc. raised its position in Boston Scientific by 32.6% during the second quarter. Simplify Asset Management Inc. now owns 15,014 shares of the medical equipment provider’s stock valued at $641,000 after buying an additional 3,690 shares during the period. Finally, Riversedge Advisors LLC acquired a new position in Boston Scientific during the second quarter valued at $320,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported second-quarter adjusted earnings of $0.86 per share and revenue of $5.44 billion, exceeding consensus estimates of $0.83 and $5.38 billion, respectively. Revenue increased 7.5% year over year, while management highlighted approximately 7% organic sales growth and a 15% increase in adjusted EPS. Boston Scientific Q2 earnings call highlights
• Positive Sentiment: Management’s multiyear restructuring plan is intended to improve efficiency and generate roughly $500 million in savings, supporting longer-term margins despite restructuring costs of up to $800 million. Reported workforce reductions are expected to affect operations in Ireland and Costa Rica. Boston Scientific restructuring cuts
• Positive Sentiment: Penumbra reported second-quarter revenue of $390.0 million, up 14.9% year over year, with thrombectomy revenue rising 12.5% and embolization and access revenue increasing 20.0%. The results provide supportive operating momentum for Boston Scientific’s pending acquisition of Penumbra, although PEN will not issue full-year guidance during the transaction. Penumbra second-quarter financial results
• Neutral Sentiment: Analyst sentiment remains broadly constructive but more cautious: UBS reaffirmed a Buy rating with a $74 target, while TD Cowen and Truist maintained Buy ratings despite lowering targets to $56 and $57. Argus reiterated a Hold rating, and BTIG reduced its expectations.
• Negative Sentiment: Boston Scientific lowered its full-year outlook because of headwinds affecting its electrophysiology and WATCHMAN portfolios. Analysts also cited a reset in expectations for these businesses, limiting the near-term upside from the earnings beat. Boston Scientific lowered full-year guidance
• Negative Sentiment: A recall involving the Rapid Refill Continuous Injection System adds a product and execution risk, while the restructuring will create near-term charges before expected savings are realized. Boston Scientific earnings, recall and restructuring

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.